BR9910267A - Microcomprimidos de ácido fumárico - Google Patents

Microcomprimidos de ácido fumárico

Info

Publication number
BR9910267A
BR9910267A BR9910267-6A BR9910267A BR9910267A BR 9910267 A BR9910267 A BR 9910267A BR 9910267 A BR9910267 A BR 9910267A BR 9910267 A BR9910267 A BR 9910267A
Authority
BR
Brazil
Prior art keywords
tablets
fumaric acid
cation
optionally
acid micro
Prior art date
Application number
BR9910267-6A
Other languages
English (en)
Inventor
Rejendra Dr Kumarjorshi
Hans-Peter Dr Strebel
Original Assignee
Fumapharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fumapharm Ag filed Critical Fumapharm Ag
Publication of BR9910267A publication Critical patent/BR9910267A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Soft Magnetic Materials (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Patente de Invenção: <B>"MICROCOMPRIMIDOS DE áCIDO FUMáRICO"<D>. A presente invenção refere-se ao uso de um ou mais sais de monoalquil ésteres de ácido fumárico da fórmula geral opcionalmente em mistura com fumarato de dialquila da fórmula onde A é um cátion bivalente das séries consistindo em Ca, Mg, Zn ou Fe ou um cátion monovalente das séries Li, Na ou K, respectivamente, e n representa o numeral 1 ou 2 dependendo do tipo de cátion, e, opcionalmente, excipientes e veículos farmaceuticamente comumente usados para preparação de uma composição farmacêutica na forma de microcomprimidos ou micropéletes para o tratamento de artrite psoriática, neurodermatite, psoríase e Crohn regionalis enteritis.
BR9910267-6A 1998-10-20 1999-10-08 Microcomprimidos de ácido fumárico BR9910267A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19848260A DE19848260C2 (de) 1998-10-20 1998-10-20 Fumarsäure-Mikrotabletten
PCT/EP1999/007568 WO2000023068A2 (de) 1998-10-20 1999-10-08 Fumarsäure-mikrotabletten

Publications (1)

Publication Number Publication Date
BR9910267A true BR9910267A (pt) 2001-01-09

Family

ID=7885018

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910267-6A BR9910267A (pt) 1998-10-20 1999-10-08 Microcomprimidos de ácido fumárico

Country Status (27)

Country Link
US (1) US6355676B1 (pt)
EP (1) EP1123092B1 (pt)
JP (1) JP3550091B2 (pt)
CN (1) CN1235578C (pt)
AT (1) ATE222760T1 (pt)
AU (1) AU745889B2 (pt)
BG (1) BG64836B1 (pt)
BR (1) BR9910267A (pt)
CA (1) CA2329543C (pt)
CZ (1) CZ300005B6 (pt)
DE (2) DE19848260C2 (pt)
DK (1) DK1123092T3 (pt)
EE (1) EE04796B1 (pt)
ES (1) ES2182568T3 (pt)
HK (1) HK1041216B (pt)
HU (1) HU229384B1 (pt)
IL (1) IL140891A (pt)
MX (1) MXPA01003966A (pt)
NO (1) NO328720B1 (pt)
NZ (1) NZ508065A (pt)
PL (1) PL193119B1 (pt)
PT (1) PT1123092E (pt)
RS (1) RS49775B (pt)
RU (1) RU2210366C2 (pt)
SK (1) SK286191B6 (pt)
TR (1) TR200003505T2 (pt)
WO (1) WO2000023068A2 (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
EP1372634B1 (de) 2001-01-12 2009-11-11 Biogen Idec International GmbH Verwendung von fumarsäureamiden
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
US6613800B1 (en) * 2001-12-03 2003-09-02 Steven A. Smith Method and compositions for treating psoriasis, eczema, seborrhea and arthritis
DE10217314A1 (de) * 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
EP1663197B1 (en) * 2003-09-09 2007-12-05 Fumapharm AG The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
PL2801354T3 (pl) * 2004-10-08 2017-08-31 Forward Pharma A/S Kompozycje farmaceutyczne o kontrolowanym uwalnianiu zawierające ester kwasu fumarowego
US20080004344A1 (en) * 2004-11-10 2008-01-03 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ATE455783T1 (de) * 2005-07-07 2010-02-15 Aditech Pharma Ag Neue glucopyranoseester und glucofuranoseester von fumarsäurealkylestern und deren pharmazeutische verwendung
US20080227847A1 (en) * 2005-07-07 2008-09-18 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
PT1762231E (pt) * 2005-08-19 2010-12-13 Verla Pharm Microcomprimidos de magnésio de libertação retardada
EP1940382A2 (en) * 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
JP2009510137A (ja) * 2005-10-07 2009-03-12 アディテック・ファルマ・アクチボラゲット フマル酸エステルを含む制御放出医薬組成物
RS63489B1 (sr) 2007-02-08 2022-09-30 Biogen Ma Inc Kompozicije i upotrebe za tretiranje multiple skleroze
WO2008096271A2 (en) * 2007-02-08 2008-08-14 Ralf Gold Neuroprotection in demyelinating diseases
DK2334378T3 (da) 2008-08-19 2014-07-07 Xenoport Inc Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse
EP3295936A1 (en) * 2009-01-09 2018-03-21 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
US9422226B2 (en) 2011-06-08 2016-08-23 Biogen Ma Inc. Process for preparing high purity and crystalline dimethyl fumarate
RU2014125430A (ru) 2011-11-24 2015-12-27 Синтон Бв Контролируемое высвобождение частиц, содержащих диметилфумарат
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
EP2811994A4 (en) 2012-02-07 2016-01-13 Biogen Ma Inc PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE
TWI486339B (zh) 2012-02-07 2015-06-01 Xenoport Inc □啉烷基反丁烯二酸化合物、醫藥組成物以及使用之方法
US20140056973A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug
CA2882713A1 (en) * 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US20140171504A1 (en) * 2012-12-14 2014-06-19 Georgia Regents Research Institute, Inc. Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters
US20140179779A1 (en) 2012-12-21 2014-06-26 Biogen Idec Ma Inc. Deuterium Substituted Fumarate Derivatives
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
SG11201507371RA (en) 2013-03-14 2015-10-29 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various deseases
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
US20160206587A1 (en) 2013-08-26 2016-07-21 Forward Pharma A/S Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
JP2016534133A (ja) 2013-09-06 2016-11-04 ゼノポート，インコーポレイティド （ｎ，ｎ−ジエチルカルバモイル）メチル メチル（２ｅ）ブト−２−エン−１，４−ジオエートの結晶形態、その合成方法及び使用
US20150079180A1 (en) 2013-09-18 2015-03-19 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate
KR102335289B1 (ko) 2013-12-12 2021-12-06 알미랄, 에스.에이. 디메틸 푸마레이트를 포함하는 약학적 조성물
JP6337135B2 (ja) 2014-02-24 2018-06-06 アルカーメス ファーマ アイルランド リミテッド フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用
EP3501510B1 (en) 2014-02-28 2020-07-01 Banner Life Sciences LLC Controlled release enteric soft capsules of fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2016061393A1 (en) 2014-10-15 2016-04-21 Xenoport, Inc. Fumarate compounds, pharmaceutical compositions, and methods of use
CN104490849A (zh) * 2014-11-24 2015-04-08 广东东阳光药业有限公司 一种高密度的富马酸二甲酯肠溶颗粒及其制备方法
US10213411B2 (en) 2015-08-27 2019-02-26 Vijaykumar Rajasekhar Use of prodrugs of fumarates in treating heart failure diseases
WO2017060400A1 (en) 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions
US10463642B2 (en) 2016-02-01 2019-11-05 Vijaykumar Rajasekhar Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate
WO2020094767A1 (en) 2018-11-08 2020-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of nrf2 activators for the treatment of staphylococcus aureus infections
AU2020283238B2 (en) 2019-05-31 2022-07-07 Curacle Co., Ltd. Enteric tablet containing dimethyl fumarate
CN110898164A (zh) * 2019-12-19 2020-03-24 赣州安宏环保科技有限公司 根除胃肠病幽门螺杆菌感染的富马酸单乙酯钙盐及其用途
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
KR20220133807A (ko) 2021-03-25 2022-10-05 주식회사 큐라클 특정 약동학적 매개변수를 나타내는 디메틸푸마레이트를 유효성분으로 함유한 약학적 조성물
WO2024047248A1 (en) 2022-09-02 2024-03-07 Institut National de la Santé et de la Recherche Médicale Use of nrf2 activators for the treatment of cerebral small vessel disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530372A1 (de) * 1975-07-08 1977-01-13 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
DE2621214C3 (de) * 1976-05-13 1981-11-12 Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen
US5149695A (en) * 1985-01-15 1992-09-22 Speiser Peter P Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same
CH664150A5 (de) * 1985-01-15 1988-02-15 Peter Paul Prof Dr Speiser Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
US5424332A (en) * 1987-10-19 1995-06-13 Speiser; Peter P. Pharmaceutical composition and process for the production thereof
DE3834794A1 (de) 1988-10-12 1990-04-19 F Schielein Oral zu verabreichendes mittel zur behandlung von psoriasis
DE19721099C2 (de) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten

Also Published As

Publication number Publication date
EP1123092A2 (de) 2001-08-16
HUP0103999A2 (hu) 2002-02-28
US6355676B1 (en) 2002-03-12
DE59902490D1 (de) 2002-10-02
CZ2001871A3 (cs) 2001-07-11
CZ300005B6 (cs) 2009-01-14
DE19848260A1 (de) 2000-05-18
DK1123092T3 (da) 2002-10-14
RS49775B (sr) 2008-06-05
NO20005239D0 (no) 2000-10-18
HK1041216B (zh) 2006-06-30
SK5392001A3 (en) 2001-08-06
EE200100030A (et) 2002-06-17
PL193119B1 (pl) 2007-01-31
ES2182568T3 (es) 2003-03-01
EP1123092B1 (de) 2002-08-28
YU65500A (sh) 2002-09-19
JP3550091B2 (ja) 2004-08-04
HU229384B1 (en) 2013-11-28
NO328720B1 (no) 2010-05-03
AU6090699A (en) 2000-05-08
NO20005239L (no) 2001-05-21
WO2000023068A2 (de) 2000-04-27
CN1323206A (zh) 2001-11-21
JP2002527475A (ja) 2002-08-27
NZ508065A (en) 2003-08-29
HUP0103999A3 (en) 2003-11-28
BG64836B1 (bg) 2006-06-30
AU745889B2 (en) 2002-04-11
ATE222760T1 (de) 2002-09-15
PL344528A1 (en) 2001-11-05
HK1041216A1 (en) 2002-07-05
WO2000023068A3 (de) 2000-07-27
RU2210366C2 (ru) 2003-08-20
CN1235578C (zh) 2006-01-11
CA2329543A1 (en) 2000-04-27
SK286191B6 (sk) 2008-05-06
DE19848260C2 (de) 2002-01-17
MXPA01003966A (es) 2002-08-20
CA2329543C (en) 2007-02-06
PT1123092E (pt) 2003-01-31
TR200003505T2 (tr) 2001-07-23
BG104836A (en) 2001-04-30
EE04796B1 (et) 2007-04-16
IL140891A (en) 2005-09-25
IL140891A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
BR9910267A (pt) Microcomprimidos de ácido fumárico
BRPI9815772A (pt) emprego de hidrogeno fumaratos de alquila para tratamento de psoríase, artrite psoriática, neurodermatites e enterite regional de crohn
BR9809655A (pt) Uso de derivados do ácido fumárico
IL83510A (en) Pharmaceutical compositions containing dipyridamole or mopidamol and o-acetylsalicylic acid or salts thereof and their preparation
BRPI9609414B8 (pt) combinação de vacina e kit para produzir a mesma.
DE69212882D1 (de) Gallensäuresalze enthaltende magenstabile pharmazeutische Zusammensetzung zur oralen Verabreichung
ES8406075A1 (es) Un procedimiento para la preparacion de una sal de adicion de un acido bencenosulfonico de la sultamicilina.
AU6048086A (en) Bactericidal formulations for use in the area of veterinary medicine
BR9907025A (pt) Polissacarìdeos sintéticos, processo para sua preparação e composições farmacêuticas que contêm os mesmos
ES2142430T3 (es) Compuestos farmaceuticos en forma de gel conteniendo sales de sulfato de condroitina apropiadas para administracion oral.
BR9915729A (pt) Amidas Èmega de n-arilsulfonil-aminoácido
BR0016419A (pt) Método para o aumento das respostas de imunização com relação a vacina do vìrus do herpes simplex
ATE22879T1 (de) Pharmazeutische zusammensetzungen und verfahren zu deren herstellung.
DE69100954D1 (de) Lagerstabile orale Glucosaminsulfat-Dosisformen und Verfahren zu deren Herstellung.
BR0109139A (pt) Composições farmacêuticas incluindo alginatos
AU570446B2 (en) Dipyridamole controlled release compositon
ATE27699T1 (de) 2&#39;.4&#39;-difluor-4-hydroxy-(1,1&#39; diphenyl)-3carboxyl-derivate von n-acetylcystein und von s- carboxymethylcystein mit entzuendungshemmender und mucolytischer wirkung, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen.
EG17992A (en) Preparation of a medicament for arthritis and theumatism
AR008764A1 (es) Sales hidratadas de n,n&#39;-diacetilcistina, proceso para su preparacion, y composiciones terapeuticas que comprenden a dichas sales como ingredienteactivo.
SE8204792D0 (sv) N-metyl-d-glukaminsalt av 3,4-dihydro-5-metyl-6-(2-metyl-propyl)-4-oxotieno(2,3-d)pyrimidin-2-karboxylsyra och farmaceutisk komposition innehallande detta salt
CU22599A1 (es) Hemoderivado en polvos para la profilaxis y tratamiento de la deficiencia de hierro
IT1255268B (it) Composizione farmaceutica ad attivita&#39; antitosse

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 9/20, A61K 31/225

Ipc: A61K 31/225 (2007.10), A61K 31/28 (2007.10), A61K

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11 E 13 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.